A phase II tolerability trial of neoadjuvant docetaxel with carboplatin and capecitabine in locally advanced breast cancer

Aruna Mani, Sandra X. Franco, Grace Wang, Neil Abramson, Lee S. Schwartzberg, James Jakub, Elizabeth Tan-Chiu, Michael A. Schwartz, Cynthia Frankel, Elisa A. Krill-Jackson, Alisha Stein, Alejandra Perez, Charles Vogel

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

This multicenter phase II trial evaluated the tolerability and efficacy of neoadjuvant chemotherapy in locally advanced breast cancer with four 28-day cycles of dose-dense chemotherapy: weekly docetaxel (30 mg/m2) and carboplatin (AUC 2) on days 1, 8, and 15, plus capecitabine (625 mg/m2) twice daily on days 5-18. The primary endpoint was pathologic complete response (pCR). Among the 49 treated patients, 89% of intended chemotherapy doses (including capecitabine) were administered. In the intent-to-treat patients, grade 4 toxicities were depression (2%) and leukopenia (8%). There were no neutropenic fevers or treatment-related deaths. Of the 41 evaluable patients who received all four chemotherapy cycles, 6 (15%) achieved a pCR; all of them had negative axillary nodes. None of the patients with pCR had developed recurrent disease at a median follow-up of 48 months. We conclude that preoperative docetaxel, carboplatin, and capecitabine has an acceptable toxicity profile and a pCR rate comparable with that seen in many other phase II neoadjuvant chemothera.

Original languageEnglish
Pages (from-to)209-215
Number of pages7
JournalCommunity Oncology
Volume8
Issue number5
StatePublished - May 1 2011

Fingerprint

docetaxel
Carboplatin
Breast Neoplasms
Drug Therapy
Leukopenia
Area Under Curve
Fever
Capecitabine

ASJC Scopus subject areas

  • Oncology
  • Hematology

Cite this

Mani, A., Franco, S. X., Wang, G., Abramson, N., Schwartzberg, L. S., Jakub, J., ... Vogel, C. (2011). A phase II tolerability trial of neoadjuvant docetaxel with carboplatin and capecitabine in locally advanced breast cancer. Community Oncology, 8(5), 209-215.

A phase II tolerability trial of neoadjuvant docetaxel with carboplatin and capecitabine in locally advanced breast cancer. / Mani, Aruna; Franco, Sandra X.; Wang, Grace; Abramson, Neil; Schwartzberg, Lee S.; Jakub, James; Tan-Chiu, Elizabeth; Schwartz, Michael A.; Frankel, Cynthia; Krill-Jackson, Elisa A.; Stein, Alisha; Perez, Alejandra; Vogel, Charles.

In: Community Oncology, Vol. 8, No. 5, 01.05.2011, p. 209-215.

Research output: Contribution to journalArticle

Mani, A, Franco, SX, Wang, G, Abramson, N, Schwartzberg, LS, Jakub, J, Tan-Chiu, E, Schwartz, MA, Frankel, C, Krill-Jackson, EA, Stein, A, Perez, A & Vogel, C 2011, 'A phase II tolerability trial of neoadjuvant docetaxel with carboplatin and capecitabine in locally advanced breast cancer', Community Oncology, vol. 8, no. 5, pp. 209-215.
Mani A, Franco SX, Wang G, Abramson N, Schwartzberg LS, Jakub J et al. A phase II tolerability trial of neoadjuvant docetaxel with carboplatin and capecitabine in locally advanced breast cancer. Community Oncology. 2011 May 1;8(5):209-215.
Mani, Aruna ; Franco, Sandra X. ; Wang, Grace ; Abramson, Neil ; Schwartzberg, Lee S. ; Jakub, James ; Tan-Chiu, Elizabeth ; Schwartz, Michael A. ; Frankel, Cynthia ; Krill-Jackson, Elisa A. ; Stein, Alisha ; Perez, Alejandra ; Vogel, Charles. / A phase II tolerability trial of neoadjuvant docetaxel with carboplatin and capecitabine in locally advanced breast cancer. In: Community Oncology. 2011 ; Vol. 8, No. 5. pp. 209-215.
@article{a7e14af4a2ce4032916459f120e9f0fd,
title = "A phase II tolerability trial of neoadjuvant docetaxel with carboplatin and capecitabine in locally advanced breast cancer",
abstract = "This multicenter phase II trial evaluated the tolerability and efficacy of neoadjuvant chemotherapy in locally advanced breast cancer with four 28-day cycles of dose-dense chemotherapy: weekly docetaxel (30 mg/m2) and carboplatin (AUC 2) on days 1, 8, and 15, plus capecitabine (625 mg/m2) twice daily on days 5-18. The primary endpoint was pathologic complete response (pCR). Among the 49 treated patients, 89{\%} of intended chemotherapy doses (including capecitabine) were administered. In the intent-to-treat patients, grade 4 toxicities were depression (2{\%}) and leukopenia (8{\%}). There were no neutropenic fevers or treatment-related deaths. Of the 41 evaluable patients who received all four chemotherapy cycles, 6 (15{\%}) achieved a pCR; all of them had negative axillary nodes. None of the patients with pCR had developed recurrent disease at a median follow-up of 48 months. We conclude that preoperative docetaxel, carboplatin, and capecitabine has an acceptable toxicity profile and a pCR rate comparable with that seen in many other phase II neoadjuvant chemothera.",
author = "Aruna Mani and Franco, {Sandra X.} and Grace Wang and Neil Abramson and Schwartzberg, {Lee S.} and James Jakub and Elizabeth Tan-Chiu and Schwartz, {Michael A.} and Cynthia Frankel and Krill-Jackson, {Elisa A.} and Alisha Stein and Alejandra Perez and Charles Vogel",
year = "2011",
month = "5",
day = "1",
language = "English",
volume = "8",
pages = "209--215",
journal = "Community Oncology",
issn = "1548-5315",
publisher = "BioLink Communications",
number = "5",

}

TY - JOUR

T1 - A phase II tolerability trial of neoadjuvant docetaxel with carboplatin and capecitabine in locally advanced breast cancer

AU - Mani, Aruna

AU - Franco, Sandra X.

AU - Wang, Grace

AU - Abramson, Neil

AU - Schwartzberg, Lee S.

AU - Jakub, James

AU - Tan-Chiu, Elizabeth

AU - Schwartz, Michael A.

AU - Frankel, Cynthia

AU - Krill-Jackson, Elisa A.

AU - Stein, Alisha

AU - Perez, Alejandra

AU - Vogel, Charles

PY - 2011/5/1

Y1 - 2011/5/1

N2 - This multicenter phase II trial evaluated the tolerability and efficacy of neoadjuvant chemotherapy in locally advanced breast cancer with four 28-day cycles of dose-dense chemotherapy: weekly docetaxel (30 mg/m2) and carboplatin (AUC 2) on days 1, 8, and 15, plus capecitabine (625 mg/m2) twice daily on days 5-18. The primary endpoint was pathologic complete response (pCR). Among the 49 treated patients, 89% of intended chemotherapy doses (including capecitabine) were administered. In the intent-to-treat patients, grade 4 toxicities were depression (2%) and leukopenia (8%). There were no neutropenic fevers or treatment-related deaths. Of the 41 evaluable patients who received all four chemotherapy cycles, 6 (15%) achieved a pCR; all of them had negative axillary nodes. None of the patients with pCR had developed recurrent disease at a median follow-up of 48 months. We conclude that preoperative docetaxel, carboplatin, and capecitabine has an acceptable toxicity profile and a pCR rate comparable with that seen in many other phase II neoadjuvant chemothera.

AB - This multicenter phase II trial evaluated the tolerability and efficacy of neoadjuvant chemotherapy in locally advanced breast cancer with four 28-day cycles of dose-dense chemotherapy: weekly docetaxel (30 mg/m2) and carboplatin (AUC 2) on days 1, 8, and 15, plus capecitabine (625 mg/m2) twice daily on days 5-18. The primary endpoint was pathologic complete response (pCR). Among the 49 treated patients, 89% of intended chemotherapy doses (including capecitabine) were administered. In the intent-to-treat patients, grade 4 toxicities were depression (2%) and leukopenia (8%). There were no neutropenic fevers or treatment-related deaths. Of the 41 evaluable patients who received all four chemotherapy cycles, 6 (15%) achieved a pCR; all of them had negative axillary nodes. None of the patients with pCR had developed recurrent disease at a median follow-up of 48 months. We conclude that preoperative docetaxel, carboplatin, and capecitabine has an acceptable toxicity profile and a pCR rate comparable with that seen in many other phase II neoadjuvant chemothera.

UR - http://www.scopus.com/inward/record.url?scp=79958818349&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79958818349&partnerID=8YFLogxK

M3 - Article

VL - 8

SP - 209

EP - 215

JO - Community Oncology

JF - Community Oncology

SN - 1548-5315

IS - 5

ER -